2022
Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening
Leapman MS, Wang R, Park H, Yu JB, Sprenkle PC, Cooperberg MR, Gross CP, Ma X. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening. JAMA Oncology 2022, 8: 41-47. PMID: 34762100, PMCID: PMC8587214, DOI: 10.1001/jamaoncol.2021.5143.Peer-Reviewed Original ResearchConceptsProstate cancer screeningUS Preventive Services Task ForcePSA testingCancer screeningInterrupted time series analysisCohort studyUS Preventive Services Task Force (USPSTF) recommendationDraft statementLarge national cohort studyEligible beneficiariesPSA testing ratesRetrospective cohort studyRate of PSANational cohort studyProstate-specific antigenAge-adjusted ratesTask Force recommendationsUSPSTF guidelinesMedian ageGuideline changesProstate cancerMedian numberMAIN OUTCOMEClaims dataTesting rates
2021
Emergency department visits for radiation cystitis among patients with a prostate cancer history
Lee V, An Y, Park HS, Yu JB, Kim SP, Jairam V. Emergency department visits for radiation cystitis among patients with a prostate cancer history. BJU International 2021, 130: 208-216. PMID: 34806813, DOI: 10.1111/bju.15650.Peer-Reviewed Original ResearchMeSH KeywordsCystitisEmergency Service, HospitalHumansMaleProstateProstatic NeoplasmsRetrospective StudiesUrinary RetentionConceptsProstate cancer historyRadiation cystitisED visitsInvasive proceduresCancer historyProstate cancerRadiation therapyHigher median total chargesNationwide Emergency Department SampleEmergency department visitsEmergency Department SampleMedian total chargesPrior prostatectomyUrinary retentionBlood transfusionDepartment visitsMedian lengthEmergency departmentNational burdenSecondary diagnosisPrimary diagnosisHospital characteristicsPotential complicationsEffective modalityInvasive measuresAdoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management
Leapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management. JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.Peer-Reviewed Original ResearchConceptsProstate magnetic resonance imagingMagnetic resonance imagingHospital referral regionsProportion of patientsProstate cancerGenomic testingCohort studyReferral regionsRetrospective cohort studyProstate cancer carePatient-level analysisCommercial insurance claimsProstate cancer managementUS hospital referral regionsYears of ageProportion of menPatients 40Definitive treatmentCancer careTesting uptakeHRR levelMAIN OUTCOMECancer managementPatientsRegional uptakeCost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer
Lester-Coll NH, Ades S, Yu JB, Atherly A, Wallace HJ, Sprague BL. Cost-effectiveness of Prostate Radiation Therapy for Men With Newly Diagnosed Low-Burden Metastatic Prostate Cancer. JAMA Network Open 2021, 4: e2033787. PMID: 33439266, PMCID: PMC7807293, DOI: 10.1001/jamanetworkopen.2020.33787.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsCost-Benefit AnalysisHumansMaleProstatic NeoplasmsQuality-Adjusted Life YearsRadiotherapyTumor BurdenConceptsMetastatic prostate cancerMetastatic hormone-sensitive prostate cancerProstate radiation therapyEconomic evaluationProstate cancerHealth-state utility estimatesIncremental cost-effectiveness ratioRadiation therapyLow-volume metastatic hormone-sensitive prostate cancerProbabilistic sensitivity analysesLow burden metastatic prostate cancerLow-volume metastatic prostate cancerCost-effectiveness ratioHormone-sensitive prostate cancerDominant treatment strategyBase case scenarioFailure-free survivalUS dollarsNet costUtility estimatesDominant strategyCost-effective treatmentHigher QALYsQALYDeprivation therapy
2020
Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients
Miccio JA, Talcott WJ, Jairam V, Park HS, Yu JB, Leapman MS, Johnson SB, King MT, Nguyen PL, Kann BH. Quantifying treatment selection bias effect on survival in comparative effectiveness research: findings from low-risk prostate cancer patients. Prostate Cancer And Prostatic Diseases 2020, 24: 414-422. PMID: 32989262, DOI: 10.1038/s41391-020-00291-3.Peer-Reviewed Original ResearchConceptsProstate cancer-specific survivalLow-risk prostate cancerExternal beam radiotherapyTreatment selection biasOverall survivalRadical prostatectomyProstate cancerOS differenceLow-risk prostate cancer patientsCancer-specific survivalEnd Results (SEER) databaseProstate cancer patientsClinical trial designEffectiveness researchComparative effectiveness researchPropensity-score matchingMethodsThe SurveillanceTreatment guidelinesResults databaseEntire cohortResultsA totalCancer patientsTreatment modalitiesNational registryPatient managementTrends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer
Nguyen KA, Lee A, Patel SA, Chakravorty A, Yu JB, Kishan AU, Chang AJ. Trends in Use and Comparison of Stereotactic Body Radiation Therapy, Brachytherapy, and Dose-Escalated External Beam Radiation Therapy for the Management of Localized, Intermediate-Risk Prostate Cancer. JAMA Network Open 2020, 3: e2017144. PMID: 32970153, PMCID: PMC7516602, DOI: 10.1001/jamanetworkopen.2020.17144.Peer-Reviewed Original ResearchConceptsStereotactic body radiation therapyBody radiation therapyRadiation therapyProstate cancerIntermediate-risk prostate cancerExternal beam radiation therapyManagement of LocalizedExternal beam radiotherapyUse of brachytherapyBeam radiation therapyCohort studyBeam radiotherapyTherapyDisease managementCancerBrachytherapyPatientsRadiotherapyNational trends in the management of patients with positive surgical margins at radical prostatectomy
Ghabili K, Park HS, Yu JB, Sprenkle PC, Kim SP, Nguyen KA, Ma X, Gross CP, Leapman MS. National trends in the management of patients with positive surgical margins at radical prostatectomy. World Journal Of Urology 2020, 39: 1141-1151. PMID: 32562045, DOI: 10.1007/s00345-020-03298-6.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyPositive surgical marginsUse of ADTPost-prostatectomy radiation therapyRadiation therapySurgical marginsRadical prostatectomyInitial courseNode-negative prostate cancerPost-operative radiation therapyMultivariable logistic regression modelNational Cancer DatabaseAdverse pathologic featuresManagement of patientsPost-operative managementLogistic regression modelsDeprivation therapySurgical cancersPrimary endpointRT useSecondary endpointsPathologic characteristicsPathologic featuresUninsured statusCancer DatabaseUltrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials
Lehrer E, Kishan A, Yu J, Trifiletti D, Showalter T, Ellis R, Zaorsky N. Ultrahypofractionated versus hypofractionated and conventionally fractionated radiation therapy for localized prostate cancer: A systematic review and meta-analysis of phase III randomized trials. Radiotherapy And Oncology 2020, 148: 235-242. PMID: 32505965, DOI: 10.1016/j.radonc.2020.04.037.Peer-Reviewed Original ResearchConceptsConventionally fractionated radiation therapyHypofractionated radiation therapyUltrahypofractionated radiation therapyLate grade 2Radiation therapyGrade 2Weighted random effects meta-analysesSummary effect sizesLocalized prostate cancerCompare treatment modalitiesDerSimonian and Laird methodPhase III protocolsRandom-effects meta-analysesGenitourinary toxicityEffects meta-analysesGastrointestinal toxicityProspective trialsMedian ageProstate cancerTreatment modalitiesComparing patientsIII protocolLaird methodTherapyMeta-analysisGeographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening
Yang DX, Makarov DV, Gross CP, Yu JB. Geographic-Level Association of Contemporary Changes in Localized and Metastatic Prostate Cancer Incidence in the Era of Decreasing PSA Screening. Cancer Control 2020, 27: 1073274820902267. PMID: 32003227, PMCID: PMC7003204, DOI: 10.1177/1073274820902267.Peer-Reviewed Original ResearchMeSH KeywordsAgedEarly DiagnosisHumansIncidenceMaleMass ScreeningProstate-Specific AntigenProstatic NeoplasmsConceptsMetastatic prostate cancer incidenceProstate cancer incidenceHealth care service areasMetastatic diseaseCancer incidenceNational Cancer Institute's SurveillanceEnd Results (SEER) databaseLocalized prostate cancerSEER 18 registriesProstate-specific antigenPSA screeningLocalized diseaseResults databaseProstate cancerOlder menMetastatic incidenceIncidenceDiseaseDiagnosisLate changesMenRecent increaseAssociationRegistryCancer
2019
Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database
Mahal A, Butler S, Franco I, Muralidhar V, Larios D, Pike L, Zhao S, Sanford N, Dess R, Feng F, D’Amico A, Spratt D, Yu J, Nguyen P, Rebbeck T, Mahal B. Conservative management of low‐risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. Cancer 2019, 125: 3338-3346. PMID: 31251398, DOI: 10.1002/cncr.32332.Peer-Reviewed Original ResearchConceptsLow-risk prostate cancerPositive biopsy coresShort-term outcomesBiopsy coresProstate cancerManagement of low-risk prostate cancerOlder patientsProstate cancer-specific mortality ratesConservative managementProstate cancer-specific mortalityCancer-specific mortality ratesActive surveillance/watchful waitingRate of conservative managementOlder menCancer-specific mortalityShort-term safetyQuality-of-life implicationsDefinitive treatmentYounger patientsOverall mortalityPatientsMortality rateProstateNational databaseCancerModerate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer
Beckta J, Nosrati J, Yu J. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urologic Oncology Seminars And Original Investigations 2019, 37: 619-627. PMID: 30738746, DOI: 10.1016/j.urolonc.2019.01.015.Peer-Reviewed Original ResearchConceptsModerate hypofractionationRadiation therapyStereotactic body radiation therapyProstate cancer radiation therapyTreatment of prostate cancerCancer radiation therapyReduced duration of treatmentDuration of treatmentStandard of careCurative intentProstate cancerHigh dosesHypofractionationReduced durationDaily sessionsFractionation schemeTherapyEffective alternativeTreatmentProstatePatientsCancerDoseMonthsCareUnderutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer
Wang C, Raldow A, Nickols N, Nguyen P, Spratt D, Dess R, Yu J, King C, Chu F, Chamie K, Litwin M, Saigal C, Reiter R, Liu S, Rettig M, Chang A, Steinberg M, Kupelian P, Kishan A. Underutilization of Androgen Deprivation Therapy with External Beam Radiotherapy in Men with High-grade Prostate Cancer. European Urology Oncology 2019, 4: 327-330. PMID: 31411981, DOI: 10.1016/j.euo.2019.01.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrogen AntagonistsAndrogensHumansMaleMedicareProstatic NeoplasmsRetrospective StudiesUnited StatesConceptsConcomitant androgen deprivation therapyAndrogen deprivation therapyExternal beam radiotherapyDefinitive external beam radiotherapyHigh-grade prostate cancerGleason grade groupProstate cancerBeam radiotherapyDeprivation therapyGG 4NHW menDuration of androgen deprivation therapyAA menPopulation-based retrospective studyProstate cancer patientsMultiple randomized trialsNon-HispanicInverse probability treatmentSurvival benefitNon-Hispanic white menRetrospective studyRandomized trialsGrade groupRadiotherapyProbability treatment
2018
Medicare Cancer Screening in the Context of Clinical Guidelines
Maroongroge S, Yu J. Medicare Cancer Screening in the Context of Clinical Guidelines. American Journal Of Clinical Oncology 2018, 41: 339-347. PMID: 26886947, DOI: 10.1097/coc.0000000000000272.Peer-Reviewed Original ResearchConceptsCancer screeningScreening ratesFee-for-serviceColorectal cancer screening ratesBilling codesCancer screening ratesColorectal screening testsMedicare fee-for-serviceMedicare Part B beneficiariesMonte Carlo permutation methodMedicare FFS populationBeneficiaries per yearMedicare FFS programEvidence-based guidelinesScreening testRetrospective claims dataProstate cancer screeningPublic health issueMammography ratesFFS populationScreening trendsMedicare populationClaims dataGuideline publicationPatient preferencesAndrogen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer
Yang D, Krasnova A, Nead K, Choueiri T, Hu J, Hoffman K, Yu J, Spratt D, Feng F, Trinh Q, Nguyen P. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Annals Of Oncology 2018, 29: 386-391. PMID: 29267861, DOI: 10.1093/annonc/mdx744.Peer-Reviewed Original ResearchConceptsAndrogen deprivation therapyDuration of androgen deprivation therapyProstate cancerIncreased riskRheumatoid arthritisDeprivation therapyAutoimmune conditionsAdverse effects of ADTStage I-III prostate cancerEffects of androgen deprivation therapyCompeting risks Cox regressionPharmacological androgen deprivation therapyRA diagnosisLocalized prostate cancerKaplan-Meier ratesRisks Cox regressionInverse probability of treatment weightingProbability of treatment weightingHistory of RACohort of elderly menDiagnosis of RARisk of rheumatoid arthritisUntreated hypogonadismImmunosuppressive propertiesAutoimmune diseases
2017
Travel distance and stereotactic body radiotherapy for localized prostate cancer
Mahal B, Chen Y, Sethi R, Padilla O, Yang D, Chavez J, Muralidhar V, Hu J, Feng F, Hoffman K, Martin N, Spratt D, Yu J, Orio P, Nguyen P. Travel distance and stereotactic body radiotherapy for localized prostate cancer. Cancer 2017, 124: 1141-1149. PMID: 29231964, DOI: 10.1002/cncr.31190.Peer-Reviewed Original ResearchMeSH KeywordsAgedHumansMaleMiddle AgedPatient Acceptance of Health CareProstateProstatic NeoplasmsRadiosurgerySocioeconomic FactorsTravelUnited StatesConceptsStereotactic body radiotherapyProstate stereotactic body radiotherapyNational Cancer Data BaseLocalized prostate cancerShort-term efficacyProstate cancerTreated with definitive external beam radiotherapyDefinitive external beam radiotherapyDefinitive stereotactic body radiotherapyLong-term clinical implicationsFavorable disease characteristicsExternal beam radiotherapyAssociated with increased adjusted oddsMultivariate logistic regressionAcademic treatment centerAffluent zip codesBeam radiotherapyTreatment optionsDisease characteristicsRadiotherapyAdjusted oddsTreatment decisionsWhite raceYounger ageJoinpoint regressionPoint: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery.
Yu J, Hamstra D. Point: Which Treatment Modality for Localized Prostate Cancer Yields Superior Quality of Life: Radiotherapy or Prostatectomy? Quality of Life is Better After Modern Radiotherapy Compared With Surgery. Oncology 2017, 31: 830-2, 835. PMID: 29179251.Peer-Reviewed Original ResearchProstate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance
Mahal A, Mahal B, Nguyen P, Yu J. Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. Cancer 2017, 124: 752-759. PMID: 29084350, DOI: 10.1002/cncr.31106.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityMetastatic diseaseCancer-specific mortalityProstate cancer outcomesOutcomes of patientsMedicaid insuranceEnd Results ProgramReceipt of therapyStage of diseaseAfrican American patientsInsurance statusPrivately insured cohortDefinitive treatmentProstate cancerLocalized CaPResults ProgramPrivate insuranceCAP outcomesCancer outcomesAmerican patientsPatientsProstateRacial disparitiesAssociated with raceAssociated with racial disparitiesRacial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States
Mahal B, Chen Y, Muralidhar V, Mahal A, Choueiri T, Hoffman K, Hu J, Sweeney C, Yu J, Feng F, Kim S, Beard C, Martin N, Trinh Q, Nguyen P. Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States. Annals Of Oncology 2017, 28: 1098-1104. PMID: 28453693, DOI: 10.1093/annonc/mdx041.Peer-Reviewed Original ResearchConceptsProstate cancer-specific mortalityProstate-specific antigenUnited States Preventive Services Task ForceRisk of prostate cancer-specific mortalityProstate cancer outcomesBlack raceMetastatic diseaseCancer outcomesProstate-specific antigen screeningRate of metastatic diseasePSA screening guidelinesCancer-specific mortalityRisk of poor outcomesStage of presentationPreventive Services Task ForceScreening-eligible ageMultivariate logistic regressionEligible populationNon-black menSEER databaseProstate cancerBlack menScreening guidelinesPoor outcomeRisk regressionHypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales
Yu J. Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales. Journal Of Clinical Oncology 2017, 35: jco.2017.72.701. PMID: 28355114, DOI: 10.1200/jco.2017.72.7016.Peer-Reviewed Original Research
2016
Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer
Lester-Coll N, Johnson S, Magnuson W, Goldhaber S, Sher D, D'Amico A, Yu J. Weighing Risk of Cardiovascular Mortality Against Potential Benefit of Hormonal Therapy in Intermediate-Risk Prostate Cancer. Journal Of The National Cancer Institute 2016, 109: djw281. PMID: 28040795, DOI: 10.1093/jnci/djw281.Peer-Reviewed Original ResearchConceptsIntermediate-risk prostate cancerQuality-adjusted life yearsHormone therapyHistory of myocardial infarctionCardiac risk factorsBiochemical failureProstate cancerRadiation therapyCardiac riskProbability of biochemical failureMonths of hormone therapyRisk factorsMyocardial infarctionYears of follow-upBenefits of HTRisk of cardiovascular mortalityDisease recurrence riskCardiac risk groupsComparing quality-adjusted life-yearsYoung menRecurrence riskFollow-upRisk groupsCardiovascular mortalityLow risk